Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb 1;56(2):131-8.
doi: 10.1097/QAI.0b013e3181ffa4f5.

Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana

Kathleen M Powis  1 , Laura Smeaton, Anthony Ogwu, Shahin Lockman, Scott Dryden-Peterson, Erik van Widenfelt, Jean Leidner, Joseph Makhema, Max Essex, Roger L Shapiro
Affiliations

Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana

Kathleen M Powis et al. J Acquir Immune Defic Syndr. .

Abstract

Background: The impact of in utero exposure to highly active antiretroviral therapy (HAART) on longitudinal growth of HIV-uninfected infants is unknown.

Methods: The Mashi and Mma Bana PMTCT intervention trials enrolled HIV-infected pregnant women at four sites in Botswana. Breast-fed (BF), HIV-uninfected infants born at 37 weeks or greater were included in this analysis. Weight-for-age (WAZ), length-for-age (LAZ), and weight-for-length (WLZ) z-scores were calculated using World Health Organization Child Growth Standards. Mean z-scores were compared between in utero antiretroviral exposure groups using Student t test, response profiles analysis, and general linear mixed effects modeling.

Results: Growth of 619 HAART-exposed and 440 zidovudine-exposed, HIV-uninfected infants was evaluated. Mean birth weights were 3.01 kg for HAART and 3.15 kg for zidovudine-exposed infants (P < 0.001) with lower mean birth WAZ, length-for-age (LAZ), and weight-for-length (WLZ) among HAART-exposed infants (all P < 0.001). HAART-exposed infants had greater improvement in WAZ and weight-for-length (WLZ) from birth through 2 months (P = 0.03, P < 0.001, respectively). The WAZ did not differ between groups from 3 through 6 months (P = 0.26). Length-for-age (LAZ) remained lower in HAART-exposed infants but the incidence of wasting or stunting did not differ between exposure groups.

Conclusions: Lower weights in HAART-exposed uninfected infants at birth were rapidly corrected during the first 6 months of life.

Trial registration: ClinicalTrials.gov NCT00197587 NCT00270296.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest: No authors have a commercial or other association that might pose a conflict of interest (e.g., pharmaceutical stock ownership, consultancy, advisory board membership, relevant patents, or research funding).

Figures

Figure 1
Figure 1. Mashi and Mma Bana Mother-Infant Pair Antiretroviral Exposures for Breast Fed Infants
1 Beginning in Oct 2002, HAART became available through the national program. Women enrolled in the Mashi Study with CD4+ counts < 200 cells/mm3 were offered HAART. 2 In Aug 2002, as a result of efficacy data from a trial in Thailand, the peripartum intervention was revised to eliminate infant placebo and provide open label nevirapine to all infants to be given as a single dose within 72 hours of birth. 3 Infants in the ZDV exposure group remained on oral prophylactic ZDV up to a maximum of six months throughout the period of breast feeding. sdNVP = single dose nevirapine, ZDV = zidovudine, BF= breast feeding, 3TC = lamivudine, rtv = ritonavir
Figure 2
Figure 2
Study Eligibility
Figure 3
Figure 3
Response profile analysis modeling for mean infant z-scores by ARV exposure status
See this image and copyright information in PMC

References

    1. Shapiro R, Hughes M, Ogwu A, Kitch D, et al. Antiretroviral Regimens in Pregnancy and Breast-Feeding in Botswana. N Engl J Med. 2010;362:2282–2294. - PMC - PubMed
    1. Marazzi MC, Nielsen-Saines K, Buonomo E, et al. Increased Infant Human Immunodeficiency Virus-Type One Free Survival at One Year of Age in Sub-Saharan Africa with Maternal Use of Highly Active Antiretroviral Therapy During Breast-Feeding. Pediatr Infect Dis J. 2009;28:483–487. - PubMed
    1. Awino J, Zeh C, Bondo P, et al. CD4 and Viral Load Response and Adherence among ART-naive Women in a Trial of HAART for PMTCT in Kisumu, Kenya [Abstract 760]. 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles.
    1. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of Mother-to-Child Transmission of HIV-1 Through Breastfeeding by Treating Mothers With Triple Antiretroviral Therapy in Dar es Salaam, Tanzania: The Mitra Plus Study. J Acquir Immune Defic Syndr. 2009;52:406–416. - PubMed
    1. Arendt V, Ndimubanzi P, Vyankandondera J, et al. AMATA study: effectiveness of antiretroviral therapy in breastfeeding mothers to prevent post-natal vertical transmission in Rwanda [TuAX102]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007; Sydney, Australia.

Publication types

Associated data